Corporate information

Ksilink opens it capital for pre-seed and seed investments.

In the field of phenotypic, patient based high throughput screening and drug discovery we offer an attractive investment opportunity to support our growth trajectory, in order to establish Ksilink as the leading company and to allow us to continue to build our therapeutics pipeline and continue to evolve our technological approach. Please find attached some information about our business outlook.

Born from the Ksilink Association’s proven track record, we are now on a bold mission to become Europe’s leading patient-centered engine for drug discovery.​

The Ksilink Association has been created in 2015 with the mission to foster patient-based drug discovery in the heart of Europe through collaborations with a network of renowned partners from academia and biotechs. Our company, Ksilink Services SAS, has emerged from this dynamic ecosystem with a dedicated team equipped with cutting-edge expertise and state-of-the-art technology, driven by the ambition to become Europe’s leading patient-centered discovery engine for novel drug candidates.

Name: Ksilink ​

Legal name: Ksilink Services SAS​

Form: Limited company (“SAS” stands for “Société par actions simplifiée”)​

Creation: December 7, 2021​

Share capital: 900,000€ ​

Registered: in France under SIREN number 908 717 796​

VAT number: FR22908717796​

Headquarters: 16 rue Ankara 67000 Strasbourg, France​

President: Ksilink Association, represented by Alain Beretz​

CEO: Antoine de Lacombe​

Information available as of 29.08.2025​